BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 10070888)

  • 1. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers.
    Jernvall P; Mäkinen MJ; Karttunen TJ; Mäkelä J; Vihko P
    Br J Cancer; 1999 Feb; 79(5-6):903-8. PubMed ID: 10070888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological and genetic abnormalities in prediction of recurrence in radically operated colorectal cancer.
    Jernvall P; Mäkinen MJ; Karttunen TJ; Mäkelä J; Vihko P
    Anticancer Res; 1999; 19(2B):1357-62. PubMed ID: 10365106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q.
    Sarli L; Bottarelli L; Bader G; Iusco D; Pizzi S; Costi R; D'Adda T; Bertolani M; Roncoroni L; Bordi C
    Dis Colon Rectum; 2004 Sep; 47(9):1467-82. PubMed ID: 15486743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival.
    Edler D; Kressner U; Ragnhammar P; Johnston PG; Magnusson I; Glimelius B; Påhlman L; Lindmark G; Blomgren H
    Clin Cancer Res; 2000 Feb; 6(2):488-92. PubMed ID: 10690528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of heterozygosity on chromosomes 2p, 3p, 18q21.3 and 11p15.5 as a poor prognostic factor in stage II and III (FIGO) cervical cancer treated by radiotherapy.
    Kozlowski L; Filipowski T; Rucinska M; Pepinski W; Janica J; Skawronska M; Poznanski J; Wojtukiewicz MZ
    Neoplasma; 2006; 53(5):440-3. PubMed ID: 17013540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping of genetic deletions on chromosome 3 in colorectal cancer: loss of 3p25-pter is associated with distant metastasis and poor survival.
    Tsai MH; Fang WH; Lin SH; Tzeng ST; Huang CS; Yen SJ; Chou SJ; Yang YC
    Ann Surg Oncol; 2011 Sep; 18(9):2662-70. PubMed ID: 21347784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective assessment of allelic losses at 4p14-16 in colorectal cancer: two mutational patterns and a locus associated with poorer survival.
    Arribas R; Ribas M; Risques RA; Masramon L; Tórtola S; Marcuello E; Aiza G; Miró R; Capellà G; Peinado MA
    Clin Cancer Res; 1999 Nov; 5(11):3454-9. PubMed ID: 10589758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity at 18q21 region in gastric cancer involves a number of cancer-related genes and correlates with stage and histology, but lacks independent prognostic value.
    Candusso ME; Luinetti O; Villani L; Alberizzi P; Klersy C; Fiocca R; Ranzani GN; Solcia E
    J Pathol; 2002 May; 197(1):44-50. PubMed ID: 12081203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMAD4 as a prognostic marker in colorectal cancer.
    Alazzouzi H; Alhopuro P; Salovaara R; Sammalkorpi H; Järvinen H; Mecklin JP; Hemminki A; Schwartz S; Aaltonen LA; Arango D
    Clin Cancer Res; 2005 Apr; 11(7):2606-11. PubMed ID: 15814640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of tumor localization on the prognostic value of P53 protein in colorectal adenocarcinomas.
    Diez M; Medrano M; Mugüerza JM; Ramos P; Hernandez P; Villeta R; Martín A; Noguerales F; Ruiz A; Granell J
    Anticancer Res; 2000; 20(5C):3907-12. PubMed ID: 11268475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of 18q LOH in sporadic colorectal carcinoma.
    Pilozzi E; Ferri M; Onelli MR; Mercantini P; Corigliano N; Duranti E; Dionisi L; Felicioni F; Virgilio E; Ziparo V; Ruco L
    Am Surg; 2011 Jan; 77(1):38-43. PubMed ID: 21396303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer.
    Tatsumoto N; Hiyama E; Murakami Y; Imamura Y; Shay JW; Matsuura Y; Yokoyama T
    Clin Cancer Res; 2000 Jul; 6(7):2696-701. PubMed ID: 10914712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer.
    Vermeulen PB; Van den Eynden GG; Huget P; Goovaerts G; Weyler J; Lardon F; Van Marck E; Hubens G; Dirix LY
    Br J Cancer; 1999 Jan; 79(2):316-22. PubMed ID: 9888475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Loss of heterozygosity involving DCC gene in human colorectal cancers is correlated with the metastatic potential].
    Gao S; Xu W; Wan Y
    Zhonghua Zhong Liu Za Zhi; 1996 Jul; 18(4):250-2. PubMed ID: 9387312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma.
    Lindforss U; Fredholm H; Papadogiannakis N; Gad A; Zetterquist H; Olivecrona H
    Cancer; 2000 Jun; 88(12):2661-7. PubMed ID: 10870047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A study on the loss of heterozygosity at the APC/MCC and DCC genetic loci in colorectal cancers].
    Lui Y; Fang D; Lu R
    Zhonghua Nei Ke Za Zhi; 1996 Jul; 35(7):439-43. PubMed ID: 9592312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity of TP53 is not correlated with clinicopathological variables in sporadic colorectal carcinomas.
    González-Aguilera JJ; Herrero MP; Maillo C; Moreno-Azcoita M; Fernández-Peralta AM
    Anticancer Res; 1999; 19(2A):1325-9. PubMed ID: 10368694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of heterozygosity on chromosome 6p21.2 as a potential marker for recurrence after radiotherapy of human cervical cancer.
    Harima Y; Harima K; Sawada S; Tanaka Y; Arita S; Ohnishi T
    Clin Cancer Res; 2000 Mar; 6(3):1079-85. PubMed ID: 10741737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indication and efficacy of adjuvant chemotherapy with oral fluoropyrimidines for dukes' B colorectal cancer.
    Yoshimatsu K; Umehara A; Ishibashi K; Yokomizo H; Yoshida K; Fujimoto T; Watanabe K; Ogawa K
    Anticancer Res; 2006; 26(4B):3089-93. PubMed ID: 16886639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.